Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Aptamer Group Plc ( (GB:APTA) ) is now available.
Aptamer Group has reported £190,000 of new fee-for-service contracts and extensions, largely driven by repeat Optimer® development work with top‑tier global pharmaceutical companies, lifting its FY26 fee-for-service order book to more than £2.1 million and reinforcing the growing adoption of its platform. The company also received its first £80,000 in cash licensing receipts from a non-exclusive hot‑start PCR Optimer® licence, a high-margin income stream that is expected, based on customer forecasts, to cover around 15% of annual overhead over the next three years, while additional licensing opportunities in diagnostics, tools and therapeutics, combined with a cash runway to June 2027, bolster revenue visibility and management’s confidence in ongoing growth and progress towards cash-flow break-even.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.88 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Spark’s Take on GB:APTA Stock
According to Spark, TipRanks’ AI Analyst, GB:APTA is a Neutral.
The score is held back primarily by very weak financial performance (sharp revenue decline, ongoing losses, and negative cash flows). Technicals are the main offset, showing a clear uptrend with supportive momentum. Valuation remains constrained by unprofitability and the absence of dividend information.
To see Spark’s full report on GB:APTA stock, click here.
More about Aptamer Group Plc
Aptamer Group plc, listed on AIM, develops next-generation synthetic binders under its Optimer® platform for the life sciences industry, supplying customised molecules used in pharmaceuticals, diagnostics, life-science tools and therapeutics. The company focuses on fee-for-service discovery and development programmes for major pharmaceutical and research partners while building a portfolio of licensing and royalty-bearing assets to create higher-margin, recurring revenue streams.
Average Trading Volume: 5,850,238
Technical Sentiment Signal: Hold
Current Market Cap: £23.6M
For detailed information about APTA stock, go to TipRanks’ Stock Analysis page.